Answers are grounded in this paper and cite their sources.
TP53-altered myelodysplastic syndrome with excess blasts and TP53-altered acute myeloid leukemia should be considered under one unifying classification term for their study in clinical trials. Ultimately, such a unification would simplify the screening processes for clinical trials and allow a focus on treating the patient for a genetically defined disorder rather than one based on an arbitrary blast threshold.
No takes yet. Share an insight, caveat, or question.
Shallis et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: